I wanted to discuss Tocilizumab. I know it has bee
Post# of 148278
They have started phase 3 (severe patients) a couple weeks ahead of us, and they can begin interim results analysis after the first 60 patients. They are ahead of us and have a lot more resources. Now efficacy could be less than Leronlimab, but first to strike will be huge. Also they are approved for other indications and supply wouldn’t be an issue.
Thoughts? Please don’t just list side effects and dismiss this drug. It is IMO our biggest competitor.
I am long CYDY but this covid play puts us in a fierce field of competition.